Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. develops late clinical-stage biopharmaceutical programs for cardiometabolic and inflammatory diseases. Company news centers on clinical development of enobosarm, an oral selective androgen receptor modulator being studied with GLP-1 receptor agonist therapy to make weight reduction more selective for fat loss while preserving lean mass, physical function, and bone.
Recurring updates also cover sabizabulin, an oral microtubule disruptor being developed for chronic inflammation related to atherosclerotic cardiovascular disease. Veru’s announcements commonly include fiscal results, business updates, clinical-study progress, regulatory feedback, scientific presentations, and conference webcasts tied to its small-molecule pipeline.
Veru Inc. (NASDAQ: VERU) announced that its CEO, Mitchell Steiner, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 12 pm ET. The presentation will outline the company's corporate strategy focusing on the clinical development of drug candidates targeting COVID-19 and oncology, with Phase 3 clinical trial data expected in 2024. A live webcast of the event will be available on the company’s website, with an archived version to follow. Veru specializes in developing treatments for infectious diseases and oncology and has FDA-approved products in its sexual health program.
On March 2, 2023, Veru announced that the FDA declined its request for Emergency Use Authorization (EUA) for sabizabulin, a treatment for hospitalized adults with moderate to severe COVID-19 at high risk for Acute Respiratory Distress Syndrome (ARDS). The FDA cited unknown influences affecting the study despite agreeing the Phase 3 trial met its primary endpoint. However, the FDA expressed willingness to collaborate on a new Phase 3 study that could lead to an EUA or NDA approval. The company continues to seek authorization for sabizabulin from other regulatory agencies globally.
Veru Inc. (NASDAQ: VERU) announced significant updates regarding sabizabulin, which is under review for emergency authorization to treat COVID-19 by multiple global regulatory agencies. A late-breaker presentation at IDWeek revealed an 81.2% relative reduction in deaths compared to placebo in severe COVID-19 patients. Financially, the company reported a decrease in net revenues to $2.5 million from $14.1 million year-over-year and an operating loss of $35.6 million. Cash reserves decreased to $46.9 million. Veru is actively enrolling in clinical trials for cancer treatments and optimizing revenue strategies in its sexual health program.
Veru Inc. has scheduled a conference call and audio webcast for February 9, 2023, at 8:00 a.m. ET to discuss its fiscal 2023 first quarter financial results and provide a business update. The call will cover key developments related to its product pipeline, including sabizabulin for COVID-19 and enobosarm for oncology. Notably, sabizabulin has shown a 51.6% reduction in deaths in its Phase 3 trial, and its review is pending by various regulatory authorities, including the U.S. FDA. Investors can access the webcast on the company's website, and a replay will be available for three months.
Veru Inc. (NASDAQ: VERU) has appointed David D. Ho, M.D., as the Chairman of its Scientific Advisory Board (SAB). Dr. Ho, a renowned expert in infectious disease research, will help drive the clinical development of Veru’s infectious disease program, particularly focusing on sabizabulin, a new treatment for COVID-19. Earlier studies showed that sabizabulin reduced mortality by 55.2% in high-risk patients. Dr. Ho's expertise is expected to bolster Veru's efforts in bringing innovative therapies to market for COVID-19 and other viral diseases.
Veru Inc. (NASDAQ: VERU) announced that the U.S. FDA is reviewing its Emergency Use Authorization (EUA) application for sabizabulin to treat hospitalized COVID-19 patients at high risk for ARDS. The company reported a net loss of $83.8 million for fiscal 2022, with total revenues decreasing to $39.4 million from $61.3 million in 2021. Despite a decline in FC2 revenue due to challenges with telemedicine customers, Veru is preparing for commercialization of sabizabulin. The company also highlighted ongoing clinical trials for various cancer treatments, including enobosarm and sabizabulin.
Veru Inc. (NASDAQ: VERU) will host a conference call on December 5, 2022, at 8:00 a.m. ET to discuss its fiscal 2022 fourth quarter and full year financial results. The company focuses on developing treatments for COVID-19 and oncology. The Phase 3 study of sabizabulin, an oral treatment for severe COVID-19, demonstrated a 55.2% reduction in mortality compared to placebo. Veru is also advancing its oncology programs, including enobosarm for breast cancer and its prostate cancer portfolio.
Veru Inc. (NASDAQ: VERU) reported the results of the FDA’s Pulmonary-Allergy Drugs Advisory Committee meeting regarding sabizabulin for Emergency Use Authorization (EUA) in hospitalized COVID-19 patients at high risk for ARDS. The committee voted 8-5 against the use of sabizabulin, citing that its benefits do not outweigh risks. A Phase 3 trial showed a 20.5% absolute reduction in mortality at 60 days among treated patients. Veru aims to collaborate with the FDA on further clinical trials while navigating the regulatory landscape for sabizabulin in the ongoing COVID-19 crisis.
Veru Inc. (NASDAQ: VERU) announced promising results from a Phase 3 trial of sabizabulin for hospitalized COVID-19 patients requiring supplemental oxygen. Presented at IDWeek 2022, findings indicated a 55.2% relative reduction in mortality and significant decreases in ICU stays and mechanical ventilation days. In patients with comorbidities, there was an 81.2% relative reduction in deaths. Sabizabulin showed good tolerability, and the trial's success has led to plans for emergency use authorization discussions with the FDA.
Veru Inc. (NASDAQ: VERU) announced that data from its Phase 3 trial of sabizabulin for hospitalized COVID-19 patients requiring supplemental oxygen will be presented at IDWeek 2022, occurring from October 19-23 in Washington, D.C. The late-breaking presentation, titled 'Clinical Benefit of Oral sabizabulin for Hospitalized Adults with COVID-19 on Supplemental Oxygen', is scheduled for October 21, 2022. The trial shows sabizabulin resulted in a 55.2% relative reduction in deaths compared to placebo, leading to a request for Emergency Use Authorization from the FDA.